Study of T Cell Aging and Chemo in Young TNBC Patients
Part of Cancer, Skin clinical trials.
This trial looks at how certain immune cells (T cells) change with age and how that might affect how well chemotherapy works in young women with triple-negative breast cancer (TNBC). It aims to learn more about why some patients respond better to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 40 or younger.
- You have been diagnosed with invasive triple-negative breast cancer (ER-, PR-, HER2-).
- Your doctor recommends chemotherapy before surgery because your tumor is larger than 2 cm, or cancer has spread to lymph nodes, or you want breast-conserving surgery and need chemo first to get clear margins.
- You do not have stage IV breast cancer or a history of other cancers.
- You do not have an active infection (like HBV, HIV) or an autoimmune disease that is not cured.
- You have not had surgery in the last 3 months, and you have enough medical records for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
This trial looks at how well a chemotherapy and immunotherapy combination works for early-stage triple-negative breast cancer when no anthracycline drugs are used. It could help avoid heart-related side effects from anthracyclines while still treating the cancer effectively.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
Hear when a new Chemotherapy Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.